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A consensus statement on the use of Benzodiazepines in specialist mental health services  
Benzodiazepines are used in Primary Care, when prescribed by General Practitioners. There are practice 
guidelines available for General Practitioners in prescribing them.1 This paper focuses on the use of 
Benzodiazepines in Specialist Mental Health Services.  
General Information:  
Benzodiazepines (BDZ) are drugs which work within the central nervous system and their main effect is to 
reduce anxiety and agitation quickly. The major clinical advantages of benzodiazepines are that they are 
highly effective in reducing anxiety, they work quickly; and they have few unwanted side effects.  
Unwanted side effects include a general slowness of mental and bodily movements; this is seen especially 
in the elderly. With long term use, tolerance (whereby the person needs more medication to produce the 
same effects) and dependence (where the person finds they start to need the drug and without it they 
develop withdrawal effects) can become major disadvantages. Unwanted effects can largely be 
prevented by keeping dosages minimal and courses short (ideally 4 weeks maximum) and by careful 
patient selection. Paradoxical reactions (unexpected increases in agitated or aggressive behaviour 
secondary to drug treatment) are rare.  
Benzodiazepines are also sedative. When prescribed, patients should be warned of the risks associated 
with combining benzodiazepines with other sedative drugs or alcohol, and of the possible adverse effects 
on driving or operating machinery. Benzodiazepines are licenced for use for 4 weeks only; prescribing for 
longer than 4 weeks is known as off-label prescribing.  Off-label prescribing should usually be limited to 
consultant-level specialists who are familiar with all the alternatives and prevailing expert opinion. In 
some circumstances it may be appropriate to continue this prescribing in Primary Care (general 
practitioner-level), but best practice is by mutual agreement between both parties concerned. It is 
important to tell the patient that the drug is being used off-label and why it is thought to be appropriate 
to use the drug.  
Benzodiazepines work by increasing the efficiency of a natural brain chemical, GABA, to decrease the 
excitability of neurons. This reduces the communication between neurons and, therefore, has a calming 
effect on many of the functions of the brain.  
Benzodiazepines can be placed into one of three groups by how quickly it is eliminated from the body. 
Short-acting compounds examples are, midazolam, and triazolam. Intermediate acting examples are  
alprazolam, flunitrazepam, clonazepam, lorazepam, nitrazepam, and temazepam. Long-acting compound 
examples are diazepam, clorazepate, chlordiazepoxide, and flurazepam.   
Generally shorter acting compounds are better for the elderly, where the longer acting compounds may 
build up over time. Short acting compounds are more likely to become habit forming or create 
dependency.  
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Indications for Use  
Caution should be exercised in prescribing benzodiazepines. Benzodiazepines prescribing should 
never be purely symptom orientated, but should be used in conjunction with treatments for any 
underlying disorder.  It is vital to check whether the person might have a tendency to misuse drugs 
or alcohol, or a history of same, and if so should a referral be made to a specialist addiction 
psychiatry service.  
 
Withdrawal from alcohol  
Benzodiazepines are recognised as the treatment of choice for alcohol withdrawal. In this context the 
dosage should be tapered and discontinued within one week. Benzodiazepines are cross-tolerant with 
alcohol. This means people who are addicted to alcohol have a strong likelihood of becoming addicted to 
benzodiazepines. Benzodiazepines also have anticonvulsant properties.12,13 
 
Anxiety Disorders  
The principal indication for benzodiazepines is for short-term treatment (2 to 4weeks) of anxiety 
disorders.2 
 
or panic disorder, benzodiazepines should not be used as a first line treatment option but are an option 
for treatment resistant cases.3 They should be used with care in post-traumatic stress disorder (PTSD).4 
Benzodiazepines have no benefit on the course of bereavement and may inhibit psychological 
adjustment.5 While benzodiazepines have been studied and utilized to treat these conditions they are 
not part of recommended first-line therapy for any of them. However, it is acceptable to use 
benzodiazepines as adjuncts during initial treatment while waiting for definitive therapy with longer 
term medications and psychotherapy to take effect. Continuing Benzodiazepines beyond 4 weeks will 
often result in loss of effectiveness, the development of tolerance, dependence and potential for 
withdrawal syndromes, persistent adverse side effects, and interference with the effectiveness of 
definitive medication and counselling. This should be discussed with the patient before prescribing. 
Benzodiazepines taken for more than 2 weeks continuously should be tapered rather than discontinued 
abruptly. If in the judgment of the clinician, the patient will have difficulty stopping the benzodiazepines 
after the 2 to 4 week acute treatment period, then benzodiazepines should not be prescribed. 
 
Benzodiazepines will usually be reserved for the treatment of patients who have not responded to at 
least two treatments (such as after non-response to both an SSRI (selective serotonin reuptake inhibitor) 
and a psychological treatment) but concerns about potential problems in long-term use should not 
prevent their use in patients with persistent, severe, distressing and impairing anxiety symptoms.6 There 
are a minority of people, who benefit from long term use of benzodiazepines, who do not develop 
tolerance, and attempts to reduce benzodiazepines results in a relapse.6  
 
Insomnia 
Benzodiazepines are effective for the short term treatment of insomnia. Non benzodiazepines (Z) 
hypnotics may be associated with less side effects. The recommendation is that all hypnotics are only 
prescribed for 2 – 4 weeks. 
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Acute Mania or Hypomania 
Benzodiazepines are used in treating Acute Mania or Hypomania, as an adjunct to Antipsychotic or Mood 
stabilising medication.  
 
Use in Psychosis  
Benzodiazepines are used in the treatment of Psychosis.   Where a person with psychosis is extremely 
distressed, and needs to be calmed quickly, then benzodiazepines are commonly used for what is 
described as Rapid Tranquillisation, either alone7, or in combination with an antipsychotic;  a significant 
minority of patients with established psychotic illness fail to respond adequately to antipsychotics alone, 
and this can result in benzodiazepines being prescribed on a long term basis.10 There is limited evidence 
that some treatment resistant patients may benefit from a combination of antipsychotics and 
benzodiazepines, either by showing a very marked antipsychotic response or by allowing the use of 
lower-dose antipsychotic regimens.11   
 
Catatonia 
Benzodiazepines are the treatment of choice in Catatonia. Numerous studies and case reports indicate 
that benzodiazepines are rapidly effective, safe and easily administered and are therefore regarded as 
first-line treatment.11  
 
Special populations:  
Pregnancy  
There is a low but established risk of teratogenicity with benzodiazepines use  in pregnancy.14-16  Ideally 
these medications should be gradually discontinued before a planned pregnancy and this possibility 
should be discussed with any woman of childbearing age for whom they are being  prescribed. If a woman 
discovers she is pregnant and is taking benzodiazepines, she should be advised of the risks and usually 
have them gradually withdrawn as soon as possible. However, as always, a risk benefit analysis should be 
undertaken, and if other treatments such as relaxation, anxiety management, sleep hygiene and 
Cognitive Behaviour Therapy (CBT) are not effective, sometimes benzodiazepines are justified. Severe 
and persistent anxiety, in itself, can be a significant risk to foetal health. Specialist advice should be 
sought if necessary. 
Old Age   
The use of benzodiazepines in older people have been associated with adverse effects including marked 
sedation and psychomotor impairment, as well as an increased risk of hip fracture and motor vehicle 
crash, as well as the development of tolerance, dependence and withdrawal.19,20,21.. The reduced drug 
clearance as we age may be responsible for the increased susceptibility to adverse events. Adverse 
effects are reduced by using short acting benzodiazepines. Depression in older people can present with 
anxiety symptoms, this should be treated with anti depressants and psychological therapies, rather than 
benzodiazepines. Prescribing for residents in continuing care facilities present special difficulties. The 
use of benzodiazepines is less when staff receives education in geriatric care and where the 
organisational culture is supportive. Long term residents in continuing care settings need to have their 
medication reviewed regularly in line with best practice and HIQA guidelines. Benefits associated with 
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successful reduction in rates of benzodiazepine use include increased mobility and alertness, reduced 
incontinence and improved well being.22   
 
 
People with an Intellectual Disability  
The risks of benzodiazepines use includes sedation, and therefore increased risk of falls, and in addition 
inability to engage with activities during the day, so impacting on quality of life. For those who lack 
capacity to consent to treatment, pending enactment of Irish capacity legislation, reference should be 
made to relevant Medical Council Guidance and the prescriber should consult with carers and appropriate 
parties in order to determine the best interests of the patient. 
 
Patients in Prison or Forensic Settings. 
Doctors working in prison settings (where substance misuse problems occur in 65-70% of inmates) come 
under particular pressure to prescribe benzodiazepines. There is evidence that much of the medication 
prescribed in these settings is misused, sold on to others in exchange for other drugs, endangering the 
unintended end users. The most common cause of death in prison now is accidental overdose, typically of 
smuggled opiates combined with diverted benzodiazepines, and so benzodiazepines are not prescribed 
unless there is clear evidence of withdrawal from alcohol or benzodiazepines, when detoxification is 
appropriate.  
 
Substance Misuse Services / Addiction Psychiatry Services. 
Many service users attending the addiction services commonly misuse benzodiazepines in large quantities 
with other drugs in order to enhance their effects, to experience euphoric effects and an altered state of 
consciousness. They are also taken to treat withdrawals from other drugs including heroin, alcohol and 
cocaine. Other reasons for taking benzodiazepines by substance misusers include self medication for 
underlying symptoms of anxiety, panic attacks, phobic disorders, depression, post-traumatic stress 
disorder, memories of past abuse, and psychotic symptoms as part of a schizophrenic illness or not. 
Individuals with a diagnosis of emotionally unstable personality disorder tend to misuse and become 
dependent on benzodiazepines to manage associated psychic distress that they experience.  
 
Patients dependent on both benzodiazepines and opiates have been found to be more psychologically 
vulnerable than those dependent on benzodiazepines alone and may have an increased incidence of 
depression and self harm. Prescribing of benzodiazepines to substance misusers requires competency in 
this form of treatment with appropriate supervision and in most cases is best provided by secondary/ 
tertiary treatment services. Prescribing of a benzodiazepines detoxification programme should occur 
when there is clear evidence of benzodiazepine dependence.24,35 There needs to be appropariate 
assessment of dependence prior to commencement of detoxification26 i.e. positive benzodiazepine urine 
results and baseline benzodiazepines levels done, education provided about the risks of benzodiazepines, 
engagement in counselling, clear treatment goals agreed and regular review of progress. 
 
Recommended targeted psychological interventions that have been recommended include anxiety 
management, relaxation techniques, anger management, motivational enhancement approach, 
maintaining a diary of drug use, identifying triggers and maintaining factors for benzodiazepines use, 
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problem solving techniques, managing insomnia, exploring other ways of coping, relapse prevention 
strategies and Cognitive Behavioural Therapy24,25 
 
The UK Clinical Guidelines on Managing Drug Misuse and Dependence27 clearly outlines the need to 
convert sedative hypnotics/benzodiazepines to an equivalent dose of diazepam and that the lowest dose 
of diazepam that will prevent withdrawal symptoms should be prescribed. The recommended rate of 
detoxification include reducing in proportions of 1/8th of daily dose (between 1/10th and ¼) every 1-2 
weeks or every month depending on the patient’s response and that the time needed for detoxification 
can vary from 4 weeks to a year or more. 
There are circumstances when the longer term prescription of benzodiazepines maybe considered 
desirable because the alternative is deemed less beneficial.  This maybe in substance misusers with 
chronic treatment resistant anxiety, or in patients who have established dependency and are unable to 
withdraw successfully.28 There are a group of substance misusers dependent on benzodiazepines who can 
benefit from a low dose prescription of benzodiazepines in the longer term, where they no longer abuse 
benzodiazepines or crave benzodiazepines and where attempts at detoxification lead to a relapse of 
their increased benzodiazepines use. As part of their care-plan it is recommended that they are reviewed 
regularly and asked to consider a detoxification programme from benzodiazepines at regular intervals (at 
least annually) 29 On review of the treatment of co-occurring disorders with opioid addiction, SAMHSA / 
CSAT:Treatment Improvement Protocols (TIP No. 43): Medication assisted Treatment for Opioid Addiction 
in Opioid Treatment Programme 30, 31 it was recommended that patients with a history of benzodiazepines 
abuse should not be disallowed from previously prescribed benzodiazepines provided that they are 
monitored carefully and have stopped their earlier abuse. It was recognised that ongoing use maybe as a 
means to reduce the symptoms of co-occurring disorders i.e. anxiety disorders, mood disorders, 
personality disorders, schizophrenia and other psychotic disorders.   
Children. 
Although infrequently used, Benzodiazepines may have a very important role to play in managing 
children with similar presentations to adults, i.e. manic presentations, acute agitation associated with 
psychosis, or short term treatment of acute and debilitating anxiety, or as part of PTSD or generalised 
anxiety. Children and adolescents may also present with severe agitation or aggressive behaviour in the 
context of a learning difficulty, pervasive developmental disorders (Autism/Aspergers) or severe 
psychological reactions to stressful life events such as abuse and trauma. Such rapid tranquilisation may 
be necessary in the interest of the safety of the patients and those around them. When used such 
interventions are always of the shortest duration possible and regularly reviewed. Informed parental 
consent and assent are desirable whenever possible, unless one needs to act under common law due to 
the urgency of the situation. All psychotropic medication used in children is generally initiated by a 
specialist in Child Mental Health and as part of a multi-modal treatment approach.  
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Good Practice Guidelines:  
 
• This paper outlines the risks and benefits of benzodiazepine use in specific groups.  
 
• Where benzodiazepine prescription is indicated, the prescriber should ensure all risks and benefits 
are explained fully to the individual. For those who lack capacity to consent to treatment, 
pending enactment of Irish capacity legislation, reference should be made to relevant Medical 
Council Guidance and the prescriber should consult with carers and appropriate parties in order to 
determine the best interests of the patient. 
 
• At the time of benzodiazepine prescription renewal or medication review, the physician should 
discuss the risks of long-term benzodiazepine and the benefits of discontinuation (on cognition, 
mood, sleep, and energy level) and advise the patient to reduce or discontinue the 
benzodiazepines. For some patients this will be difficult or impossible, and there may be some 
cases where the psychiatrist, in partnership with the patient agrees that continuing the 
benzodiazepine medication is the best course of action. There are a group of people, for whom 
maintenance medication for their mental illness may include a low dose of benzodiazepines. 
These people do not develop tolerance to the drug, do not require higher doses, or develop 
craving for the drug, and yet attempts to reduce the benzodiazepines results in a relapse in the 
mental illness. For these people remaining on the benzodiazepines is appropriate. 
 
• The College of Psychiatry recommends that members who prescribe benzodiazepines should 
follow good practice guidelines for their use.23 This includes conducting regular audit of practice. 
Standards of practice should ensure short term use of benzodiazepines, using the lowest dose 
possible and where their use has been for longer than four weeks, clear evidence of education on 
reducing with a view to discontinuing, and if this is not possible clear documentation on reasons 
for continuing prescription.  
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